Catalyst Pharmaceuticals, Inc v. Lupin Ltd

Court

District Court, D. Delaware (D. Del.)
Official Court Website →

Assigned judge

Maryellen Noreika · 2,011 cases in index

Docket number

1:23-cv-00229

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

03/02/2023

Date terminated

05/05/2023

1,113 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Catalyst Pharmaceuticals, Inc Pharmaceuticals & Biotechnology · 11 cases
• defendant · Lupin Ltd · 127 cases

Part of a Larger Litigation Pattern

This is one of 128 Patent - ANDA cases in our index naming Lupin Ltd — a possible mass-tort or coordinated-litigation cluster.

• Oyster Point Pharma, Inc v. Lupin Ltd
  District Court, D. New JerseyFiled 11/21/2025
• Takeda Pharmaceuticals U.S.A., Inc v. Lupin, Ltd
  District Court, D. New JerseyFiled 07/01/2025
• Jazz Pharmaceuticals Ireland Limited v. Lupin Ltd
  District Court, D. New JerseyFiled 08/27/2024
• Amicus Therapeutics US, LLC v. Lupin Ltd
  District Court, D. DelawareFiled 09/01/2023
• Astellas Pharma Inc v. Lupin Ltd
  District Court, D. DelawareFiled 07/28/2023
• Novo Nordisk Inc v. Lupin Ltd
  District Court, D. New JerseyFiled 07/27/2023

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Catalyst Pharmaceuticals, Inc v. Lupin Ltd?

Catalyst Pharmaceuticals, Inc v. Lupin Ltd is a federal patent - anda lawsuit filed on 03/02/2023 in the District Court, D. Delaware. The case was terminated on 05/05/2023. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. Delaware, docket number 1:23-cv-00229.

When was the case filed?

Catalyst Pharmaceuticals, Inc v. Lupin Ltd was filed on 03/02/2023. It was terminated on 05/05/2023.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.